APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chagas Disease Treatment Market Outlook and Growth Opportunities 2026

22 December 2025201 pages

Choose your research edition.

Industry ResearchChagas Disease Treatment Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Treatment Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Chagas Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Treatment Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Treatment Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Chagas Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chagas Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chagas Disease Treatment market include Daiichi Sankyo Company Ltd, Eisai Co Ltd, ELEA SACIF Laboratory, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Inc, Kancera AB and Laboratorio Elea Phoenix SA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chagas Disease Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chagas Disease Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chagas Disease Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chagas Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chagas Disease Treatment Segment by Company

Daiichi Sankyo Company Ltd

Eisai Co Ltd

ELEA SACIF Laboratory

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Grupo Praxis Pharmaceutical SA

KaloBios Pharmaceuticals, Inc

Kancera AB

Laboratorio Elea Phoenix SA

Laboratorio Farmaceutico De Pernambuco

Maprimed S.A

Nortec Quimica SA

Novartis AG

Oblita Therapeutics BVBA

Sanofi Aventis

AstraZeneca

Bayer AG

Johnson & Johnson

Chagas Disease Treatment Segment by Type

Benznidazole

Nifurtimox

Chagas Disease Treatment Segment by Application

Hospitals

Online Pharmacies

Retail Pharmacies

Chagas Disease Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Chagas Disease Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chagas Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chagas Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Chagas Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chagas Disease Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chagas Disease Treatment industry.

Chapter 3: Detailed analysis of Chagas Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chagas Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chagas Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chagas Disease Treatment Industry Trends Table 2. Chagas Disease Treatment Industry Drivers Table 3. Chagas Disease Treatment Industry Opportunities and Challenges Table 4. Chagas Disease Treatment Industry Restraints Table 5. Global Chagas Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chagas Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Chagas Disease Treatment Sales Volume by Company (k units) & (2021-2026) Table 8. Global Chagas Disease Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Chagas Disease Treatment Average Price (US$/unit) of Company (2021-2026) Table 10. Global Chagas Disease Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chagas Disease Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Chagas Disease Treatment Company, Product Type & Application Table 13. Global Chagas Disease Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chagas Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Benznidazole Table 18. Significant Companies of Nifurtimox Table 19. Global Chagas Disease Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Chagas Disease Treatment Sales Volume by Type (2021-2026) & (k units) Table 21. Global Chagas Disease Treatment Sales Volume by Type (2027-2032) & (k units) Table 22. Global Chagas Disease Treatment Sales Volume Share by Type (2021-2026) Table 23. Global Chagas Disease Treatment Sales Volume Share by Type (2027-2032) Table 24. Global Chagas Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Chagas Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Chagas Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Chagas Disease Treatment Sales Value Share by Type (2021-2026) Table 28. Global Chagas Disease Treatment Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Online Pharmacies Table 31. Significant Companies of Retail Pharmacies Table 32. Global Chagas Disease Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Chagas Disease Treatment Sales Volume by Application (2021-2026) & (k units) Table 34. Global Chagas Disease Treatment Sales Volume by Application (2027-2032) & (k units) Table 35. Global Chagas Disease Treatment Sales Volume Share by Application (2021-2026) Table 36. Global Chagas Disease Treatment Sales Volume Share by Application (2027-2032) Table 37. Global Chagas Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Chagas Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Chagas Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Chagas Disease Treatment Sales Value Share by Application (2021-2026) Table 41. Global Chagas Disease Treatment Sales Value Share by Application (2027-2032) Table 42. Global Chagas Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Chagas Disease Treatment Sales by Region (2021-2026) & (k units) Table 44. Global Chagas Disease Treatment Sales Market Share by Region (2021-2026) Table 45. Global Chagas Disease Treatment Sales by Region (2027-2032) & (k units) Table 46. Global Chagas Disease Treatment Sales Market Share by Region (2027-2032) Table 47. Global Chagas Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Chagas Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Chagas Disease Treatment Sales Value Share by Region (2021-2026) Table 50. Global Chagas Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Chagas Disease Treatment Sales Value Share by Region (2027-2032) Table 52. Global Chagas Disease Treatment Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Chagas Disease Treatment Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Chagas Disease Treatment Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Chagas Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Chagas Disease Treatment Sales by Country (2021-2026) & (k units) Table 57. Global Chagas Disease Treatment Sales Market Share by Country (2021-2026) Table 58. Global Chagas Disease Treatment Sales by Country (2027-2032) & (k units) Table 59. Global Chagas Disease Treatment Sales Market Share by Country (2027-2032) Table 60. Global Chagas Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Chagas Disease Treatment Sales Value Market Share by Country (2021-2026) Table 62. Global Chagas Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Chagas Disease Treatment Sales Value Market Share by Country (2027-2032) Table 64. Daiichi Sankyo Company Ltd Company Information Table 65. Daiichi Sankyo Company Ltd Business Overview Table 66. Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio Table 68. Daiichi Sankyo Company Ltd Recent Development Table 69. Eisai Co Ltd Company Information Table 70. Eisai Co Ltd Business Overview Table 71. Eisai Co Ltd Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Eisai Co Ltd Chagas Disease Treatment Product Portfolio Table 73. Eisai Co Ltd Recent Development Table 74. ELEA SACIF Laboratory Company Information Table 75. ELEA SACIF Laboratory Business Overview Table 76. ELEA SACIF Laboratory Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio Table 78. ELEA SACIF Laboratory Recent Development Table 79. F. Hoffmann-La Roche Ltd. Company Information Table 80. F. Hoffmann-La Roche Ltd. Business Overview Table 81. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio Table 83. F. Hoffmann-La Roche Ltd. Recent Development Table 84. GlaxoSmithKline Plc Company Information Table 85. GlaxoSmithKline Plc Business Overview Table 86. GlaxoSmithKline Plc Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio Table 88. GlaxoSmithKline Plc Recent Development Table 89. Grupo Praxis Pharmaceutical SA Company Information Table 90. Grupo Praxis Pharmaceutical SA Business Overview Table 91. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio Table 93. Grupo Praxis Pharmaceutical SA Recent Development Table 94. KaloBios Pharmaceuticals, Inc Company Information Table 95. KaloBios Pharmaceuticals, Inc Business Overview Table 96. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio Table 98. KaloBios Pharmaceuticals, Inc Recent Development Table 99. Kancera AB Company Information Table 100. Kancera AB Business Overview Table 101. Kancera AB Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Kancera AB Chagas Disease Treatment Product Portfolio Table 103. Kancera AB Recent Development Table 104. Laboratorio Elea Phoenix SA Company Information Table 105. Laboratorio Elea Phoenix SA Business Overview Table 106. Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio Table 108. Laboratorio Elea Phoenix SA Recent Development Table 109. Laboratorio Farmaceutico De Pernambuco Company Information Table 110. Laboratorio Farmaceutico De Pernambuco Business Overview Table 111. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio Table 113. Laboratorio Farmaceutico De Pernambuco Recent Development Table 114. Maprimed S.A Company Information Table 115. Maprimed S.A Business Overview Table 116. Maprimed S.A Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Maprimed S.A Chagas Disease Treatment Product Portfolio Table 118. Maprimed S.A Recent Development Table 119. Nortec Quimica SA Company Information Table 120. Nortec Quimica SA Business Overview Table 121. Nortec Quimica SA Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Nortec Quimica SA Chagas Disease Treatment Product Portfolio Table 123. Nortec Quimica SA Recent Development Table 124. Novartis AG Company Information Table 125. Novartis AG Business Overview Table 126. Novartis AG Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Novartis AG Chagas Disease Treatment Product Portfolio Table 128. Novartis AG Recent Development Table 129. Oblita Therapeutics BVBA Company Information Table 130. Oblita Therapeutics BVBA Business Overview Table 131. Oblita Therapeutics BVBA Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio Table 133. Oblita Therapeutics BVBA Recent Development Table 134. Sanofi Aventis Company Information Table 135. Sanofi Aventis Business Overview Table 136. Sanofi Aventis Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Sanofi Aventis Chagas Disease Treatment Product Portfolio Table 138. Sanofi Aventis Recent Development Table 139. AstraZeneca Company Information Table 140. AstraZeneca Business Overview Table 141. AstraZeneca Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. AstraZeneca Chagas Disease Treatment Product Portfolio Table 143. AstraZeneca Recent Development Table 144. Bayer AG Company Information Table 145. Bayer AG Business Overview Table 146. Bayer AG Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Bayer AG Chagas Disease Treatment Product Portfolio Table 148. Bayer AG Recent Development Table 149. Johnson & Johnson Company Information Table 150. Johnson & Johnson Business Overview Table 151. Johnson & Johnson Chagas Disease Treatment Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Johnson & Johnson Chagas Disease Treatment Product Portfolio Table 153. Johnson & Johnson Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Chagas Disease Treatment Distributors List Table 157. Chagas Disease Treatment Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Chagas Disease Treatment Product Image Figure 2. Global Chagas Disease Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chagas Disease Treatment Sales (2021-2032) & (k units) Figure 5. Global Chagas Disease Treatment Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Chagas Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Benznidazole Image Figure 10. Nifurtimox Image Figure 11. Global Chagas Disease Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Chagas Disease Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Chagas Disease Treatment Sales Volume Share by Type (2021-2032) Figure 14. Global Chagas Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Chagas Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Chagas Disease Treatment Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Online Pharmacies Image Figure 19. Retail Pharmacies Image Figure 20. Global Chagas Disease Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Chagas Disease Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Chagas Disease Treatment Sales Volume Share by Application (2021-2032) Figure 23. Global Chagas Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Chagas Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Chagas Disease Treatment Sales Value Share by Application (2021-2032) Figure 26. Global Chagas Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Chagas Disease Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Chagas Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Chagas Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. North America Chagas Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Chagas Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Chagas Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. South America Chagas Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Chagas Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Chagas Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Chagas Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Chagas Disease Treatment Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Chagas Disease Treatment Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Benznidazole
  • Nifurtimox
Applications
  • Hospitals
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Daiichi Sankyo Company Ltd
  • Eisai Co Ltd
  • ELEA SACIF Laboratory
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals, Inc
  • Kancera AB
  • Laboratorio Elea Phoenix SA
  • Laboratorio Farmaceutico De Pernambuco
  • Maprimed S.A
  • Nortec Quimica SA
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sanofi Aventis
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chagas Disease Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Chagas Disease Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Chagas Disease Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chagas Disease Treatment Market Dynamics
  1. 2.1 Chagas Disease Treatment Industry Trends
  2. 2.2 Chagas Disease Treatment Industry Drivers
  3. 2.3 Chagas Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Chagas Disease Treatment Industry Restraints
3 Chagas Disease Treatment Market by Company
  1. 3.1 Global Chagas Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Chagas Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Chagas Disease Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Chagas Disease Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Chagas Disease Treatment Company Ranking (2024-2026)
  6. 3.6 Global Chagas Disease Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Chagas Disease Treatment Company Product Type and Application
  8. 3.8 Global Chagas Disease Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chagas Disease Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chagas Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chagas Disease Treatment Market by Type
  1. 4.1 Chagas Disease Treatment Type Introduction
  2. 4.1.1 Benznidazole
  3. 4.1.2 Nifurtimox
  4. 4.2 Global Chagas Disease Treatment Sales Volume by Type
  5. 4.2.1 Global Chagas Disease Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Chagas Disease Treatment Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Chagas Disease Treatment Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Chagas Disease Treatment Sales Value by Type
  9. 4.3.1 Global Chagas Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Chagas Disease Treatment Sales Value by Type (2021-2032)
  11. 4.3.3 Global Chagas Disease Treatment Sales Value Share by Type (2021-2032)
5 Chagas Disease Treatment Market by Application
  1. 5.1 Chagas Disease Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Chagas Disease Treatment Sales Volume by Application
  6. 5.2.1 Global Chagas Disease Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chagas Disease Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Chagas Disease Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Chagas Disease Treatment Sales Value by Application
  10. 5.3.1 Global Chagas Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chagas Disease Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Chagas Disease Treatment Sales Value Share by Application (2021-2032)
6 Chagas Disease Treatment Regional Sales and Value Analysis
  1. 6.1 Global Chagas Disease Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chagas Disease Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Chagas Disease Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Chagas Disease Treatment Sales by Region (2027-2032)
  5. 6.3 Global Chagas Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chagas Disease Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chagas Disease Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chagas Disease Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Chagas Disease Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chagas Disease Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Chagas Disease Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chagas Disease Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Chagas Disease Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chagas Disease Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chagas Disease Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chagas Disease Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Chagas Disease Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chagas Disease Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chagas Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Chagas Disease Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Chagas Disease Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chagas Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chagas Disease Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Chagas Disease Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Chagas Disease Treatment Sales by Country (2027-2032)
  6. 7.4 Global Chagas Disease Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chagas Disease Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chagas Disease Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chagas Disease Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chagas Disease Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chagas Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Daiichi Sankyo Company Ltd
  2. 8.1.1 Daiichi Sankyo Company Ltd Company Information
  3. 8.1.2 Daiichi Sankyo Company Ltd Business Overview
  4. 8.1.3 Daiichi Sankyo Company Ltd Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Daiichi Sankyo Company Ltd Chagas Disease Treatment Product Portfolio
  6. 8.1.5 Daiichi Sankyo Company Ltd Recent Developments
  7. 8.2 Eisai Co Ltd
  8. 8.2.1 Eisai Co Ltd Company Information
  9. 8.2.2 Eisai Co Ltd Business Overview
  10. 8.2.3 Eisai Co Ltd Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Co Ltd Chagas Disease Treatment Product Portfolio
  12. 8.2.5 Eisai Co Ltd Recent Developments
  13. 8.3 ELEA SACIF Laboratory
  14. 8.3.1 ELEA SACIF Laboratory Company Information
  15. 8.3.2 ELEA SACIF Laboratory Business Overview
  16. 8.3.3 ELEA SACIF Laboratory Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 ELEA SACIF Laboratory Chagas Disease Treatment Product Portfolio
  18. 8.3.5 ELEA SACIF Laboratory Recent Developments
  19. 8.4 F. Hoffmann-La Roche Ltd.
  20. 8.4.1 F. Hoffmann-La Roche Ltd. Company Information
  21. 8.4.2 F. Hoffmann-La Roche Ltd. Business Overview
  22. 8.4.3 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 F. Hoffmann-La Roche Ltd. Chagas Disease Treatment Product Portfolio
  24. 8.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
  25. 8.5 GlaxoSmithKline Plc
  26. 8.5.1 GlaxoSmithKline Plc Company Information
  27. 8.5.2 GlaxoSmithKline Plc Business Overview
  28. 8.5.3 GlaxoSmithKline Plc Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Plc Chagas Disease Treatment Product Portfolio
  30. 8.5.5 GlaxoSmithKline Plc Recent Developments
  31. 8.6 Grupo Praxis Pharmaceutical SA
  32. 8.6.1 Grupo Praxis Pharmaceutical SA Company Information
  33. 8.6.2 Grupo Praxis Pharmaceutical SA Business Overview
  34. 8.6.3 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Grupo Praxis Pharmaceutical SA Chagas Disease Treatment Product Portfolio
  36. 8.6.5 Grupo Praxis Pharmaceutical SA Recent Developments
  37. 8.7 KaloBios Pharmaceuticals, Inc
  38. 8.7.1 KaloBios Pharmaceuticals, Inc Company Information
  39. 8.7.2 KaloBios Pharmaceuticals, Inc Business Overview
  40. 8.7.3 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KaloBios Pharmaceuticals, Inc Chagas Disease Treatment Product Portfolio
  42. 8.7.5 KaloBios Pharmaceuticals, Inc Recent Developments
  43. 8.8 Kancera AB
  44. 8.8.1 Kancera AB Company Information
  45. 8.8.2 Kancera AB Business Overview
  46. 8.8.3 Kancera AB Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kancera AB Chagas Disease Treatment Product Portfolio
  48. 8.8.5 Kancera AB Recent Developments
  49. 8.9 Laboratorio Elea Phoenix SA
  50. 8.9.1 Laboratorio Elea Phoenix SA Company Information
  51. 8.9.2 Laboratorio Elea Phoenix SA Business Overview
  52. 8.9.3 Laboratorio Elea Phoenix SA Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Laboratorio Elea Phoenix SA Chagas Disease Treatment Product Portfolio
  54. 8.9.5 Laboratorio Elea Phoenix SA Recent Developments
  55. 8.10 Laboratorio Farmaceutico De Pernambuco
  56. 8.10.1 Laboratorio Farmaceutico De Pernambuco Company Information
  57. 8.10.2 Laboratorio Farmaceutico De Pernambuco Business Overview
  58. 8.10.3 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Laboratorio Farmaceutico De Pernambuco Chagas Disease Treatment Product Portfolio
  60. 8.10.5 Laboratorio Farmaceutico De Pernambuco Recent Developments
  61. 8.11 Maprimed S.A
  62. 8.11.1 Maprimed S.A Company Information
  63. 8.11.2 Maprimed S.A Business Overview
  64. 8.11.3 Maprimed S.A Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Maprimed S.A Chagas Disease Treatment Product Portfolio
  66. 8.11.5 Maprimed S.A Recent Developments
  67. 8.12 Nortec Quimica SA
  68. 8.12.1 Nortec Quimica SA Company Information
  69. 8.12.2 Nortec Quimica SA Business Overview
  70. 8.12.3 Nortec Quimica SA Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Nortec Quimica SA Chagas Disease Treatment Product Portfolio
  72. 8.12.5 Nortec Quimica SA Recent Developments
  73. 8.13 Novartis AG
  74. 8.13.1 Novartis AG Company Information
  75. 8.13.2 Novartis AG Business Overview
  76. 8.13.3 Novartis AG Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novartis AG Chagas Disease Treatment Product Portfolio
  78. 8.13.5 Novartis AG Recent Developments
  79. 8.14 Oblita Therapeutics BVBA
  80. 8.14.1 Oblita Therapeutics BVBA Company Information
  81. 8.14.2 Oblita Therapeutics BVBA Business Overview
  82. 8.14.3 Oblita Therapeutics BVBA Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Oblita Therapeutics BVBA Chagas Disease Treatment Product Portfolio
  84. 8.14.5 Oblita Therapeutics BVBA Recent Developments
  85. 8.15 Sanofi Aventis
  86. 8.15.1 Sanofi Aventis Company Information
  87. 8.15.2 Sanofi Aventis Business Overview
  88. 8.15.3 Sanofi Aventis Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Sanofi Aventis Chagas Disease Treatment Product Portfolio
  90. 8.15.5 Sanofi Aventis Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Chagas Disease Treatment Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Bayer AG
  98. 8.17.1 Bayer AG Company Information
  99. 8.17.2 Bayer AG Business Overview
  100. 8.17.3 Bayer AG Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Bayer AG Chagas Disease Treatment Product Portfolio
  102. 8.17.5 Bayer AG Recent Developments
  103. 8.18 Johnson & Johnson
  104. 8.18.1 Johnson & Johnson Company Information
  105. 8.18.2 Johnson & Johnson Business Overview
  106. 8.18.3 Johnson & Johnson Chagas Disease Treatment Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Johnson & Johnson Chagas Disease Treatment Product Portfolio
  108. 8.18.5 Johnson & Johnson Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chagas Disease Treatment Value Chain Analysis
  2. 9.1.1 Chagas Disease Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chagas Disease Treatment Sales Mode & Process
  6. 9.2 Chagas Disease Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chagas Disease Treatment Distributors
  9. 9.2.3 Chagas Disease Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst